



Revista Bioética

ISSN: 1983-8042

ISSN: 1983-8034

Conselho Federal de Medicina

Porto Almeida, Palloma
Bioética e medicina personalizada no envelhecimento: explorando complexidades
Revista Bioética, vol. 31, no. 1, e3588PT, 2023, October-December
Conselho Federal de Medicina

DOI: <https://doi.org/10.1590/1983-803420233588PT>

Available in: <https://www.redalyc.org/articulo.oa?id=361575107024>

- How to cite
- Complete issue
- More information about this article
- Journal's webpage in [redalyc.org](https://www.redalyc.org)

 [redalyc.org](https://www.redalyc.org)

Scientific Information System Redalyc
Network of Scientific Journals from Latin America and the Caribbean, Spain and
Portugal

Project academic non-profit, developed under the open access initiative

Bioethics and concierge medicine in aging: exploring complexities

Palloma Porto Almeida

Universidade do Estado do Rio de Janeiro, Rio de Janeiro/RJ, Brasil.

Abstract

Concierge medicine emerged as a promising approach to offer exclusive and personalized treatments using genomic tools. In aging studies, concierge medicine has the potential to transform the treatment and prevention of age-associated and related diseases through pharmacogenetics and nutrigenomics; however, its use of genomic data raises important bioethical concerns, including privacy, consent, equity issues and potential misuse of these data for discriminatory purposes. Hence, careful consideration should be given to the biomedical, social, and ethical aspects of concierge medicine in aging contexts. Our review explores the main aspects of age-related pharmacogenetics and nutrigenomics data in concierge medicine, discussing the bioethical concerns involved in its use.

Keywords: Aging. Bioethics. Pharmacogenetics. Concierge medicine. Nutrigenomics.

Resumo

Bioética e medicina personalizada no envelhecimento: explorando complexidades

A medicina personalizada surgiu como uma abordagem promissora para fornecer tratamentos exclusivos e personalizados para doenças usando ferramentas genômicas. No campo dos estudos do envelhecimento, a medicina personalizada tem grande potencial para transformar o tratamento e a prevenção de doenças associadas à idade e relacionadas à nutrigenômica e à farmacogenômica. No entanto, o uso de dados genômicos na medicina personalizada levanta preocupações bioéticas significativas, incluindo questões como privacidade, consentimento, equidade e potencial uso indevido de dados genômicos para fins discriminatórios. Portanto, é crucial considerar cuidadosamente os aspectos biomédicos, sociais e éticos da medicina personalizada no contexto de condições relacionadas à idade. Esta revisão tem o objetivo de explorar os principais aspectos da medicina personalizada concernentes a doenças relacionadas à idade nos dados farmacogenômicos e nutrigenômicos, abordando as preocupações bioéticas envolvidas no uso desses dados.

Palavras-chave: Envelhecimento. Bioética. Farmacogenética. Medicina concierge. Nutrigenômica.

Resumen

Bioética y medicina personalizada en el envejecimiento: explorar las complejidades

La medicina personalizada surgió como un enfoque prometedor con el fin de proporcionar tratamientos únicos y personalizados a enfermedades utilizando herramientas genómicas. En los estudios de envejecimiento, la medicina personalizada puede transformar el tratamiento y la prevención de enfermedades asociadas a la edad y relacionadas con la nutrigenómica y la farmacogenómica. Sin embargo, el uso de datos genómicos en medicina personalizada plantea importantes preocupaciones bioéticas, incluidos temas como la privacidad, el consentimiento, la equidad y el posible uso indebido de los datos genómicos con fines discriminatorios. Así, es fundamental ponderar cuidadosamente los aspectos biomédicos, sociales y éticos de la medicina personalizada en el contexto de las afecciones relacionadas con la edad. Esta revisión pretende explorar los principales aspectos de la medicina personalizada sobre las enfermedades relacionadas con la edad en los datos farmacogenómicos y nutrigenómicos al abordar las preocupaciones bioéticas involucradas en el uso de estos datos.

Palabras clave: Envejecimiento. Bioética. Farmacogenética. Consejería médica. Nutrigenómica.

The author declares no conflict of interest.

Concierge medicine is a method that uses genomics and biotechnology to develop individualized treatment plans for patients based on their genetic information, as well as on genomic information such as RNA, proteins, and metabolites¹. In a broader definition, concierge medicine is a health model that incorporates the principles of prediction, personalization, prevention and participation, also known as P4 medicine².

The use of genomic data as the basis for concierge medicine raises concerns about privacy, consent, equity, and the potential misuse for discriminatory purposes. Thus, the careful consideration of biomedical, social, and ethical aspects of concierge medicine in the context of age-related conditions is crucial.

The field of medicine has been transformed: the focus shifted from treating diseases to promoting well-being, which means prioritizing prevention over treatment. This paradigm shift involves the use of personalized patient information to implement proactive measures that prevent diseases before they arise, thus emphasizing a broader and more individualized approach to health care³.

Nutrigenomics, pharmacogenomics and other areas have been actively developed to promote greater health among the older population⁴⁻⁷. These fields aim to deepen the understanding of the needs of older patients, create targeted interventions to improve their health, and prevent age-related diseases (ARD).

Despite the potential benefits of using genetic data to develop necessary treatment and prevention plans, several concerns arise—especially regarding privacy, prejudice, and resistance to treatment costs⁸. The challenges of storing, sharing, and protecting genetic data must be addressed for their availability. One's genetic information may lead to discrimination, and the possibility of health care providers or insurance companies resisting to cover treatment costs.

The aforementioned concerns emphasize the need for ethical guidelines and policies that balance the potential benefits of concierge medicine while protecting the patient's privacy and rights. This review focuses on these issues and their impact on the treatment of patients with ARD. The bioethical complexities

inherent in concierge medicine, nutrigenomics, and pharmacogenomics will also be examined. This study aims to provide a comprehensive overview of these emerging fields and their potential benefits and challenges, as well as the ethical considerations implied in concierge medicine for older patient care.

Aging and related diseases

Aging can be defined as the gradual and irreversible decline of physiological function^{9,10}. The changes can affect various areas of the body, including cell, organ and metabolism function¹¹. The underlying mechanisms of aging are not yet fully understood, but they likely involve a combination of genetic, environmental, and lifestyle factors.

The impact of aging leads to an increased risk of ARD, including cardiovascular, neurodegenerative and metabolic diseases, and cancer, which also poses a significant challenge to the social and economic stability of individuals.

Neurodegenerative diseases, including Alzheimer's disease (AD), are strongly associated with aging. The characteristics of AD include the presence of amyloid plaques outside the cell, neurofibrillary tangles (NFT) within the cell, and the hyperphosphorylation of the Tau protein¹². Brain aging is characterized by a pro-inflammatory environment, altered signaling and accumulation of senescent glia¹³.

In the case of AD, the main phagocytic cells in the brain, microglia, have their neuroprotective abilities impaired, and low-grade neuroinflammation occurs^{13,14}. The presence of reactive astrocytes and the decrease in the number of neural stem cells and in the neurogenesis capacity are also associated with neurodegenerative diseases.

Senescent cells accumulate with aging and may contribute to the development and progression of cancer, promoting an inflammatory state through the expression of the senescence-associated secretory phenotype (SASP)¹⁵. The NF- κ B and p38MAPK signaling pathways are involved in SASP release, which can promote the invasion of cancer cells and epithelial-mesenchymal transition (EMT)¹⁶.

Epigenetic modifications have been identified as major contributors to cancer development and progression. Aberrant patterns of DNA methylation often seen in aging, such as hypermethylation of the p21^{WAF1/CIP1} and p16^{INK4a} genes, may lead to cancer development¹⁷. Histone modifications, including losses in histone acetylation and methylation, are often seen in cancer cells. The role of histone deacetylases (HDAC) in cancer development and progression is well established. The HDAC are closely linked to the progression and prognosis of urogenital, reproductive and gastrointestinal cancer, as well as several others¹⁸.

Aging affects the cardiovascular system, increasing the prevalence of cardiovascular diseases such as hypertension, atherosclerosis, myocardial infarction and cerebral vascular accident. Cardiovascular tissues undergo pathological changes with aging, resulting in hypertrophy, altered left ventricular diastolic function, reduced left ventricular systolic reserve capacity, increased arterial stiffness, and impaired endothelial function¹⁹.

In the last decade, the field of aging studies has presented a new hypothesis: a high-calorie diet without physical exercise may have harmful effects by inhibiting the expression of “longevity genes” that facilitate cellular defenses against aging and age-related diseases²⁰. This view is opposed to the traditional thesis that cardiovascular diseases result from the accumulation of fatty acids and cholesterol in tissues, stimulating the production of pro-inflammatory cytokines and reactive oxygen species (ROS)²¹.

Metabolic and systemic changes are known consequences of the aging process. Among these alterations, adipose tissue dysfunction is a significant characteristic, resulting in insulin resistance and chronic inflammation, and an increased risk of obesity and type 2 diabetes²². Studies suggest that molecular and cellular events that contribute to age-related damage of adipose tissue begin in the subcutaneous adipose tissue due to reduced function of resident antigen-presenting cells, increased inflammation and accumulation of senescent cells^{22,23}.

In addition, individuals with type 2 diabetes often exhibit an elevated senescent cell load in

their adipose tissue, evidenced by increased expression levels of markers such as SA- β -gal, p53, p21, and pro-inflammatory SASP components, including IL-1 α , IL-1 β , IL-6, and TNF- α ²⁴. Senescence-related hypomethylation is mainly observed in genes that have reduced expression in proliferating cells, but elevated expression in senescent cells. This includes genes encoding p53, p21 and p16 targets, as well as the two primary pro-inflammatory components of SASP, IL-6 and IL-8^{15,25}.

Chronic sterile inflammation triggered by aging and obesity can lead to a vicious cycle between senescence and DNA hypomethylation²².

Concierge medicine and age-related diseases

Nutrigenomics

Nutrigenomics studies nutrients and food structures capable of acting on gene expression, understanding how different nutrients and dietary patterns interact with an individual's DNA, affecting their health and aging process. This approach holds the potential to provide personalized dietary recommendations and interventions based on an individual's genetic makeup to prevent age-related diseases and promote healthy aging²⁶.

Single nucleotide polymorphism (SNP) may partially contribute to variations in individual responses to bioactive food components. For example, Zeisel²⁷, when investigating SNPs that alter the risk of developing organ dysfunction due to low choline intake, demonstrated that premenopausal women who carry a common SNP (methylenetetrahydrofolate dehydrogenase MTHFD1-G1958A) are 15 times more likely to exhibit choline deficiency symptoms than individuals without this SNP when on a low-choline diet²⁷.

Breast cancer risk correlates to certain genetic variants that control homocysteine metabolism, such as methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MTR). This correlation is particularly strong in individuals who have lower intakes of folate and vitamins B6 and B12²⁸.

Food can influence the expression of genes and signaling pathways involved in type 2 diabetes and cancer. Naringin, a compound abundant in citrus fruits and some vegetables, has been shown to improve β cell function and reduce insulin resistance, thus acting as a potent hypoglycemic agent through genetic interaction, increasing the activity of peroxisome proliferator-activated receptors (PPAR- γ).

On the other hand, biotin, found in various food sources such as spinach, eggs, sweet potatoes and almonds, increases insulin secretion and islet function through genetic interaction, signaling an increase in the activity of Forkhead Box A2 (FOXA2), HNF-4 α , a nuclear transcription factor and neuroendocrine/brain type calcium channel, alpha-1 subunit (CACNA1D). These findings suggest that specific bioactive compounds in food may play a significant role in regulating the expression of type 2 diabetes-related genes, showing how food compounds are related to gene expression and modulation.

Calorie restriction (CR) increases life expectancy in several organisms, such as humans, mice and non-human primates²⁹⁻³¹, perhaps due to the induction of sirtuins, especially sirtuin 1 (SIRT1)³². Activation of SIRT1 and HDAC1 by caloric restriction induces deacetylation effects that result in changes in gene expression of key aging genes, including p53, Foxo, Ku70, PGC-1 α , and p16^{INK4a}³³. The decrease in p16^{INK4a} gene expression, resulting from the activation of SIRT1 by caloric restriction, delays the aging process and extends lifespan, since p16^{INK4a} is a cyclin-dependent kinase inhibitor linked to the regulation of cellular senescence³⁴.

Calorie restriction induces stress defense mechanisms, especially those related to the detoxification of ROS in rodents, a risk factor for cancer and cardiovascular diseases³⁵. Because of this, CR has been associated with a reduction in the incidence of age-related diseases³⁶. Maintaining a healthy weight and avoiding excessive calorie intake are thus important habits⁴. This approach emphasizes the potential of nutrition to intervene in genomics, with calorie restriction being a possible strategy to promote healthy aging.

The *Drosophila* model was employed in a study to track potentially bioactive compounds

and their effects on aging-related factors in a cost-effective and rapid way, including lifespan and oxidative stress. Evangelakou and collaborators³⁷ provided examples of bioactive compounds, such as polyphenols, flavonoids, and omega-3 fatty acids, that impacted aging-related pathways in the *Drosophila* model^{38,39}. They also noted the potential of combining dietary interventions with exercise or pharmacological treatments to promote healthy aging.

These data highlight how nutrigenomics impacts the health of the older people and the development of personalized nutritional plans. However, nutrigenomics is a complex field, and the interpretation of genetic data requires specialized knowledge and experience. Receiving inaccurate or misleading information could negatively affect an individual's health. Access to accurate and reliable information is necessary, with professionals who can help in the correct interpretation and application of the information.

The potential social and cultural bias must be considered when developing personalized nutrition plans. The genetic makeup of an individual is shaped by genetic and environmental factors, including cultural and social ones. Personalized nutrition plans may be biased toward certain cultures or social groups. Thus, ensuring the development of personalized nutrition plans in a culturally sensitive and inclusive way is important.

Pharmacogenomics

Precision medicine is advancing through pharmacogenomics (PGx), which involves customizing drug selection and dosing based on a patient's genetic characteristics. Physicians have expressed enthusiasm for several potential advantages of the PGx test: providing guidance on starting new drugs, facilitating shared decision-making, and minimizing the trial-and-error process of finding an appropriate treatment regimen. These advantages are particularly valuable for older patients with comorbidities and polypharmacy⁴⁰.

In addition to genetic variations and changes in DNA methylation and chromatin structure, microRNAs (miRNA), a family of small non-coding RNAs (usually 20 to 24 nucleotides long),

are involved in the regulation of protein translation with a highly precise mechanism that adjusts gene expression in different tissues and cells⁴¹. This makes miRNAs very important epigenetic modulators, which influence the regulatory networks of genes involved in drug absorption, metabolism, and disposition. MicroRNAs have emerged as a promising therapeutic target.

In a study to identify potential precision drugs for breast cancer patients, Xu and collaborators⁴² analyzed the diaphony between different miRNA-mediated risk pathways. Using bioinformatics tools to analyze gene expression and miRNA targets in breast cancer, they identified several miRNAs involved in regulating risk pathways that could be potential targets for drug treatments. Such findings provided insights into the molecular mechanisms of breast cancer—whose incidence increases with aging—and suggested a new approach to concierge treatments.

Warfarin is an oral anticoagulant used to treat various cardiovascular conditions and is affected by SNP in the CYP2C9 and VKORC1 genes. The CYP2C9 gene metabolizes and eliminates S-warfarin and belongs to the cytochrome P450 superfamily. The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit 1, a target of warfarin. The knowledge about SNP in these genes enables concierge treatment with warfarin for cardiovascular patients. Most of the participants were older people, highlighting the contribution of pharmacogenomics to the health of the older population⁴³.

The APOE4 gene is associated with an increased AD risk, but its influence on drug effectiveness is still unclear. While initial studies suggested reduced efficacy in APOE4 carriers, later studies reported conflicting results for cholinesterase inhibitors, such as tacrine, donepezil, galantamine, and rivastigmine⁴⁴⁻⁴⁷. Associations between polymorphism in acetylcholinesterase, choline acetyltransferase, and CYP2D6, as well as differential responses to treatment, were also evaluated⁴⁸, but studies on adverse drug reactions are limited to tacrine-induced liver damage. The pharmacogenomics approach can help provide a more effective treatment for patients with AD.

Among the bioethical aspects of PGx, emphasizing considerations and principles involved in the use of genetic information to

support drug treatment decisions is important. For example, patients may have concerns about the privacy and confidentiality of their genetic information, or may feel pressured to undergo testing or treatment based on their genetic profile. The cost of pharmacogenomic testing and concierge medicine could widen the gap between the rich and the poor. Unequal access to health care and treatment is also a risk, particularly for marginalized communities, who may not have access to the latest pharmacogenomic technologies.

Final considerations

Concierge medicine has brought great hope for the prevention and treatment of AD, associated with nutrigenomics and pharmacogenomics. However, several bioethical concerns surrounding the use of genomic data for concierge medicine in aging studies require attention. One of the main concerns is the privacy of genomic data.

Patients may hesitate to undergo genetic testing for fear of discrimination based on their genetic predisposition to certain diseases. For example, an individual at high risk of developing AD may face discrimination in the workplace or by insurance companies. Thus, ensuring patients' control over their genomic data and establishing measures to protect their privacy is important.

In conclusion, these fields hold great promise for concierge medicine in AD. Nutrigenomics can provide insights into an individual's unique nutritional needs and how they may be impacted by their genetic makeup, whereas pharmacogenomics can guide personalized drug selection and dosing based on genetic characteristics.

The use of genomic data in concierge medicine raises significant bioethical concerns. Improved education and awareness around the ethical implications of concierge medicine is necessary, both for health care professionals and patients. Therefore, ensuring that patients have a thorough understanding of the risks and benefits and that they can make informed decisions about their care is important.

References

1. Institute of Medicine (United States). Integrating large-scale genomic information into clinical practice: Workshop summary. Washington: National Academies Press (US); 2012.
2. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. *N Biotechnol* [Internet]. 2012 [acesso 10 abr 2023];29(6):613-24. DOI: 10.1016/j.nbt.2012.03.004
3. Li Z, Zhang Z, Ren Y, Wang Y, Fang J, Yue H *et al*. Aging and age-related diseases: from mechanisms to therapeutic strategies. *Biogerontology* [Internet]. 2021 [acesso 10 abr 2023];22(2):165-87. DOI: 10.1007/s10522-021-09910-5
4. Riscuta G. Nutrigenomics at the interface of aging, lifespan, and cancer prevention. *J Nutr* [Internet]. 2016 [acesso 10 abr 2023];146(10):1931-9. DOI: 10.3945/jn.116.235119
5. Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. *Genes (Basel)* [Internet]. 2020 [acesso 10 abr 2023];11(6):679. DOI: 10.3390/genes11060679
6. Ryan L, Hay M, Huentelman MJ, Duarte A, Rundek T, Levin B *et al*. Precision aging: Applying precision medicine to the field of cognitive aging. *Front Aging Neurosci* [Internet]. 2019 [acesso 10 abr 2023];11:128. DOI: 10.3389/fnagi.2019.00128
7. Müllers P, Taubert M, Müller NG. Physical exercise as personalized medicine for dementia prevention? *Front Physiol* [Internet]. 2019 [acesso 10 abr 2023];10:672. DOI: 10.3389/fphys.2019.00672
8. Brothers KB, Rothstein MA. Ethical, legal and social implications of incorporating personalized medicine into healthcare. *Per Med* [Internet]. 2015 [acesso 10 abr 2023];12(1):43-51. DOI: 10.2217/pme.14.65
9. Cai Y, Song W, Li J, Jing Y, Liang C, Zhang L *et al*. The landscape of aging. *Sci China Life Sci* [Internet]. 2022 [acesso 10 abr 2023];65(12):2354-454. DOI: 10.1007/s11427-022-2161-3
10. Kirkwood TBL. Understanding the odd science of aging. *Cell* [Internet]. 2005 [acesso 10 abr 2023];120(4):437-47. DOI: 10.1016/j.cell.2005.01.027
11. Liochev S. Which is the most significant cause of aging? *Antioxidants (Basel)* [Internet]. 2015 [acesso 10 abr 2023];17;4(4):793-810. DOI: 10.3390/antiox4040793
12. Xia X, Jiang Q, McDermott J, Han JDJ. Aging and Alzheimer's disease: Comparison and associations from molecular to system level. *Aging Cell* [Internet]. 2018 [acesso 10 abr 2023];17(5):e12802. DOI: 10.1111/accel.12802
13. Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ *et al*. A transcriptomic atlas of aged human microglia. *Nat Commun* [Internet]. 2018 [acesso 10 abr 2023];9(1):539. DOI: 10.1038/s41467-018-02926-5
14. Harry GJ. Microglia during development and aging. *Pharmacol Ther* [Internet]. 2013 [acesso 10 abr 2023];139(3):313-26. DOI: 10.1016/j.pharmthera.2013.04.013
15. Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. *Nat Rev Cancer* [Internet]. 2019 [acesso 10 abr 2023];19(8):439-53. DOI: 10.1038/s41568-019-0156-2
16. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. *Annu Rev Pathol*. 2010 [acesso 10 abr 2023];5(1):99-118. DOI: 10.1146/annurev-pathol-121808-102144
17. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. *Curr Med Chem* [Internet]. 2010 [acesso 10 abr 2023];17(20):2141-51. DOI: 10.2174/092986710791299966
18. Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. *Cold Spring Harb Perspect Med* [Internet]. 2016 [acesso 10 abr 2023];6(10):a026831. DOI: 10.1101/cshperspect.a026831
19. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. *Circulation* [Internet]. 2003 [acesso 10 abr 2023];107(2):346-54. DOI: 10.1161/01.cir.0000048892.83521.58
20. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. *Circ Res* [Internet]. 2012 [acesso 10 abr 2023];110(8):1097-108. DOI: 10.1161/CIRCRESAHA.111.246876

21. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. *Mech Ageing Dev* [Internet]. 2005 [acesso 10 abr 2023];126(9):987-1002. DOI: 10.1016/j.mad.2005.03.019
22. Spinelli R, Parrillo L, Longo M, Florese P, Desiderio A, Zatterale F *et al*. Molecular basis of ageing in chronic metabolic diseases. *J Endocrinol Invest* [Internet]. 2020 [acesso 10 abr 2023];43(10):1373-89. DOI: 10.1007/s40618-020-01255-z
23. Tchkonja T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H *et al*. Fat tissue, aging, and cellular senescence. *Aging Cell* [Internet]. 2010 [acesso 10 abr 2023];9(5):667-84. DOI: 10.1111/j.1474-9726.2010.00608.x
24. Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T *et al*. A crucial role for adipose tissue p53 in the regulation of insulin resistance. *Nat Med* [Internet]. 2009 [acesso 10 abr 2023];15(9):1082-7. DOI: 10.1038/nm.2014
25. So AY, Jung JW, Lee S, Kim HS, Kang KS. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. *PLoS One* [Internet]. 2011 [acesso 10 abr 2023];6(5):e19503. DOI: 10.1371/journal.pone.0019503
26. Marcum JA. Nutrigenetics/nutrigenomics, personalized nutrition, and precision healthcare. *Curr Nutr Rep* [Internet]. 2020 [acesso 10 abr 2023];9(4):338-45. DOI: 10.1007/s13668-020-00327-z
27. Zeisel SH. Nutritional genomics: defining the dietary requirement and effects of choline. *J Nutr* [Internet]. 2011 [acesso 10 abr 2023];141(3):531-4. DOI: 10.3945/jn.110.130369
28. Jiang-Hua Q, De-chuang J, Zhen-duo L, Shu-de C, Zhenzhen L. Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes. *Tumour Biol* [Internet]. 2014 [acesso 10 abr 2023];35(12):11895-901. DOI: 10.1007/s13277-014-2456-1
29. Colman RJ, Beasley TM, Kemnitz JW, Johnson SC, Weindruch R, Anderson RM. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. *Nat Commun* [Internet]. 2014 [acesso 10 abr 2023];5(1):3557. DOI: 10.1038/ncomms4557
30. Redman LM, Ravussin E. Caloric restriction in humans: impact on physiological, psychological, and behavioral outcomes. *Antioxid Redox Signal* [Internet]. 2011 [acesso 10 abr 2023];14(2):275-87. DOI: 10.1089/ars.2010.3253
31. Weindruch R, Walford RL, Fligiel S, Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. *J Nutr* [Internet]. 1986 [acesso 10 abr 2023];116(4):641-54. DOI: 10.1093/jn/116.4.641
32. Ramis MR, Esteban S, Miralles A, Tan D-X, Reiter RJ. Caloric restriction, resveratrol and melatonin: role of SIRT1 and implications for aging and related-diseases. *Mech Ageing Dev* [Internet]. 2015 [acesso 10 abr 2023];146-148:28-41. DOI: 10.1016/j.mad.2015.03.008
33. Li Y, Daniel M, Tollefsbol TO. Epigenetic regulation of caloric restriction in aging. *BMC Med* [Internet]. 2011 [acesso 8 ago 2023];9(1):98. DOI: 10.1186/1741-7015-9-98
34. Li Y, Tollefsbol TO. p16INK4a suppression by glucose restriction contributes to human cellular lifespan extension through SIRT1-mediated epigenetic and genetic mechanisms. *PLoS One* [Internet]. 2011 [acesso 10 abr 2023];24;6(2):e17421. DOI: 10.1371/journal.pone.0017421
35. Walsh ME, Shi Y, Van Remmen H. The effects of dietary restriction on oxidative stress in rodents. *Free Radic Biol Med*. 2014 [acesso 10 abr 2023];66:88-99. DOI: 10.1016/j.freeradbiomed.2013.05.037
36. Weiss EP, Fontana L. Caloric restriction: powerful protection for the aging heart and vasculature. *Am J Physiol Circ Physiol* [Internet]. 2011 [acesso 10 abr 2023];301(4):H1205-19. DOI: 10.1152/ajpheart.00685.2011
37. Evangelakou Z, Manola M, Gumeni S, Trougakos IP. Nutrigenomics as a tool to study the impact of diet on aging and age-related diseases: the *Drosophila* approach. *Genes Nutr* [Internet]. 2019 [acesso 10 abr 2023];14(1):12. DOI: 10.1186/s12263-019-0638-6
38. Shaidi F, Nacz M. Phenolics in food and nutraceuticals [Internet]. Boca Raton: CRC; 2003 [acesso 10 abr 2023]. DOI: 10.1201/9780203508732

39. Piegholdt S, Rimbach G, Wagner AE. The phytoestrogen prunetin affects body composition and improves fitness and lifespan in male *Drosophila melanogaster*. *FASEB J* [Internet]. 2016 [acesso 10 abr 2023];30(2):948-58. DOI: 10.1096/fj.15-282061
40. Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: prescribing precisely. *Med Clin North Am* [Internet]. 2019. [acesso 10 abr 2023];103(6):977-90. DOI: 10.1016/j.mcna.2019.07.002
41. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet* [Internet]. 2011 [acesso 10 abr 2023];12(12):861-74. DOI: 10.1038/nrg3074
42. Xu Y, Lin S, Zhao H, Wang J, Zhang C, Dong Q *et al*. Quantifying risk pathway crosstalk mediated by miRNA to screen precision drugs for breast cancer patients. *Genes (Basel)* [Internet]. 2019 [acesso 10 abr 2023];10(9):657. DOI: 10.3390/genes10090657
43. Al-Eitan LN, Almasri AY, Khasawneh RH. Impact of CYP2C9 and VKORC1 Polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation therapy. *Genes (Basel)* [Internet]. 2018 [acesso 10 abr 2023];9(12):578. DOI: 10.3390/genes9120578
44. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. *Neurology* [Internet]. 1998 [acesso 10 abr 2023];50(3):669-77. DOI: 10.1212/WNL.50.3.669
45. Suh GH, Jung HY, Lee CU, Oh BH, Lee SK, Lee NJ *et al*. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. *Dement Geriatr Cogn Disord* [Internet]. 2006. [acesso 10 abr 2023];21(1):33-9. DOI: 10.1159/000089217
46. Choi SH, Kim SY, Na HR, Kim B-K, Yang DW, Kwon JC, Park MY. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. *Dement Geriatr Cogn Disord* [Internet]. 2008 [acesso 10 abr 2023];25(5):445-50. DOI: 10.1159/000124752
47. Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. *Dement Geriatr Cogn Disord* [Internet]. 2005 [acesso 10 abr 2023];20(4):254-61. DOI: 10.1159/000087371
48. Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: current state and future steps. *Ann Neurol* [Internet]. 2011 [acesso 10 abr 2023];70(5):684-97. DOI: 10.1002/ana.22502

Palloma Porto Almeida – Master – pahporto@gmail.com

 0000-0002-1588-8722

Correspondence

Palloma Porto Almeida – Rua Itabaiana, 278, ap. 402, Grajaú CEP 20561-055. Rio de Janeiro/RJ, Brasil.

Received: 5.4.2023

Revised: 7.5.2023

Approved: 7.21.2023